The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 3.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 3% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 15%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (16 analysts) rates it buy, with a mean price target of $33.
Deutsche Bank AG
DBK.DE · XETRA · EUR · Market cap $55.0B · 90,067 employees
Deutsche Bank Aktiengesellschaft, a stock corporation, provides corporate and investment banking, private clients, and asset management products and services in Germany, the United Kingdom, the rest of Europe, the Americ…
FAIL · Does not pass the screenPrice as of 13 Nov 2026Daily close, not a live quote
Screened 2026-11-13 · the tape above runs as of 06:12 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price33.19 EUR at the 13 Nov 2026 close
- Our value readUndervalued vs our fair value, as of 13 Nov 2026
- Our regime readMarkup, as of 15 Nov 2026
- Ethical screenDoes not pass
- Last reviewed13 Nov 2026 (3 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: 40.00 EUR to 66.37 EUR, base estimate 40.00 EUR (screen dated 2026-11-13).
- Trend Markup
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options no verdict drawn today, left as found
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its markup label.
Deutsche Bank AG holds its Markup at $33.19. The statistical read favours the buyers, held for 19 days.
| Phase | Markup |
| Quantitative state | The statistical read favours the buyers, held for 19 days |
| Price at the screen | $33.19 |
| Valuation | 10.50 trailing · 8.55 forward price to earnings |
| Values screen | FAIL · score 30.0 |
| Beta | 1.00 |
Five Screens, Shown in Full
Does not pass. Business activity exclusion: FAIL on business activity
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Excluded | Core business clean | Business activity exclusion: FAIL on business activity | Fail |
| Debt load | Excluded | Below 33% | Interest-bearing debt is of its assets, above the one-third ceiling the screen allows. | Fail |
| Interest-bearing cash | Excluded | Below 33% | Interest-bearing cash and securities are of assets, above the one-third limit. | Fail |
| Receivables | Excluded | Below 49% | Money owed to the company is of assets, above the 49% limit. | Fail |
| Revenue purity | Excluded | Below 5% | of revenue comes from non-compliant sources, over the 5% line. | Fail |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadWhy It Falls Short, in Plain English
Deutsche Bank does not clear the screen at the business-activity stage. It operates in an area the screen excludes: Business activity exclusion: FAIL on business activity, so the financial ratios are not the deciding factor here.
Read as at 2026-11-14. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when DBK.DE's ethical verdict changes
Today DBK.DE does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 13 Nov 2026: it trades at roughly a 17% discount to our 40.00 EUR fair value, 1.20% revenue growth.
How a fair value is estimated: discounted cash flow (DCF).
Fair value range in EUR, drawn from the 2026-11-13 screen. The gold marker is the market price at the same screen. A 17.0% discount to the base estimate.
Third-party analyst targets: 17 covering, consensus Hold. The average target sits −1% from the screen price.
Reading the gap · Our model sees value the Street hasn't fully caught up to yet.
Price History & ProjectionsWhere our models see it going: fair-value estimate 40.00 EUR, with a range of 40.00 EUR to 66.37 EUR, dated to the 2026-11-13 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsWhy it stands out
A 1%-growth business trading at just 8.6x forward earnings. That is a 17% discount to our 40.00 EUR fair value: the market is pricing it cautiously while the fundamentals argue otherwise. 17 analysts rate it Hold with a 33.00 EUR average target.
| Forward P/E | 8.6xexpensive even after accounting for its growth |
| Trailing P/E | 10.5xreasonably valued |
| EPS, trailing | 3.16 |
| EPS, forward | 3.88 |
| Revenue growth | +1.2%slow but positive growth |
| Profit margin | 22.7%healthy profit margins |
| Return on equity | 8.7%a modest return on shareholder capital |
| Dividend yield | 3.55% |
| Beta | 1.00steadier than the market |
| 52-week range | 23.70 - 34.26 |
| Market cap | $55.0B |
| Employees | 90,067 |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: its business and earnings are exposed to Germany and to currency swings.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeDBK.DE trades on XETRA (the company is based in Germany). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 1.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 15%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (16 analysts) rates it buy, with a mean price target of $33. Since the last review it its composite score eased.
The framework has shifted from accumulation to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 15%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (16 analysts) rates it buy, with a mean price target of $33.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 15%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (16 analysts) rates it buy, with a mean price target of $33.
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 15.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 15%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (16 analysts) rates it buy, with a mean price target of $33. Since the last review it its composite score eased.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 15%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (16 analysts) rates it buy, with a mean price target of $33.
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 15%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (16 analysts) rates it buy, with a mean price target of $33.
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 15%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (16 analysts) rates it buy, with a mean price target of $33.
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns.
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $26.15 | +3.6% | $1.00 | $1,075 | +7.5% |
| 2 months | $26.73 | +1.4% | $1.00 | $1,051 | +5.1% |
| 3 months | $26.18 | +3.5% | $1.00 | $1,073 | +7.3% |
| 6 months | $31.46 | -13.9% | $1.00 | $893 | -10.7% |
| 1 year | $23.54 | +15.1% | $1.00 | $1,193 | +19.3% |
| 2 years | $14.34 | +88.9% | $1.68 | $2,006 | +100.6% |
| 3 years | $8.98 | +201.8% | $2.13 | $3,255 | +225.5% |
| 5 years | $10.11 | +167.9% | $2.63 | $2,939 | +193.9% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever DBK.DE does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.